News & Press Releases

WuXi AppTec Nantong Site Receives 2025 Architizer A+Award for Its Unique Blend of Technology and Humanity

Shanghai, June 26, 2025 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, is delighted to announce that its Nantong site (Phase I) has been recognized as the Popular Choice Winner in the “Factory & Warehouse” category at the 2025 Architizer A+Awards. This recognition underscores WuXi AppTec’s commitment to creating innovative, human-centric workplaces that empower employees and support customers in delivering transformative therapies for patients.

WuXi AppTec Earns SBTi Validation for Near-Term Emissions Reduction Targets

SHANGHAI, June 17, 2025 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that the Science Based Targets initiative (SBTi) has approved WuXi AppTec’s near-term science-based emissions reduction targets. The validation of these targets affirms that the Company’s planned reduction in greenhouse gas (GHG) emissions aligns with the goal of limiting global temperature rise to 1.5°C, underscoring WuXi AppTec’s commitment to meaningful action for a more sustainable future.

WuXi AppTec Recognized by Extel 2025 Asia Executive Team Rankings with Top Honors

SHANGHAI, June 16, 2025 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been recognized among the Top 10 “Most Honored Companies” in new rankings from Extel (formerly known as Institutional Investor).

WuXi AppTec Q1 2025 Revenue, Profit Resume Double Digit Growth, Revenue Up 21.0% YoY, Adjusted Non-IFRS Net Profit Up 40.0% YoY; Backlog for Continuing Operations Up 47.1% YoY

(SHANGHAI, April 28, 2025) — WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced financial results for the first quarter ending March 31, 2025 (“Reporting Period”):

WuXi AppTec’s Changzhou and Taixing API Sites Successfully Pass FDA Inspections

Shanghai, China – March 31, 2025 — WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences industry, today announced that its Active Pharmaceutical Ingredient (API) manufacturing sites at Changzhou and Taixing in Jiangsu province of China, successfully passed U.S. Food and Drug Administration (FDA) inspections back-to-back in March — both without a single observation and with no Form 483 issued. These achievements further demonstrate WuXi AppTec’s unwavering commitment to upholding the highest quality standards and to supporting global healthcare innovators in reliably delivering needed therapies to patients worldwide.